Quest Diagnostics (DGX) received approval from the New York State Department of Health for its Haystack MRD circulating tumor DNA test, which is used to detect residual or recurrent disease in patients with solid tumors, the company said Wednesday.
The approval expands Haystack MRD availability to New York, making the test accessible in all 50 US states after being offered in 49 states and the District of Columbia since late 2024, the company said.
Price: $203.85, Change: $+6.66, Percent Change: +3.38%